Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer
Rui Li(Hunan Academy of Agricultural Sciences), Xingming Deng(Emory University), Gabriel Sica(Emory University), Walter J. Curran(Piedmont Cancer Institute), Fadlo R. Khuri(American University of Beirut Medical Center), Taofeek K. Owonikoko(UPMC Hillman Cancer Center), Suresh S. Ramalingam(Emory University), Zhongliang Hu(Central South University), Zhuo G. Chen(Emory University), Shi‐Yong Sun(Emory University)
Cited by 156
Related Papers
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
|Journal of Clinical Oncology|2013|1.1k